Clearside Biomedical Stock Earnings Per Share
| CLM Stock | EUR 1.01 0.04 4.12% |
Clearside Biomedical fundamentals help investors to digest information that contributes to Clearside Biomedical's financial success or failures. It also enables traders to predict the movement of Clearside Stock. The fundamental analysis module provides a way to measure Clearside Biomedical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Clearside Biomedical stock.
Clearside |
Clearside Biomedical Company Earnings Per Share Analysis
Clearside Biomedical's Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
| Competition |
According to the company disclosure, Clearside Biomedical has an Earnings Per Share of 0.0 times. This indicator is about the same for the average (which is currently at 0.0) sector and about the same as Earnings Per Share (which currently averages 0.0) industry. This indicator is about the same for all Germany stocks average (which is currently at 0.0).
Did you try this?
Run Pair Correlation Now
Pair CorrelationCompare performance and examine fundamental relationship between any two equity instruments |
| All Next | Launch Module |
Clearside Fundamentals
| Current Valuation | 17.17 M | |||
| Price To Book | 3.77 X | |||
| Price To Sales | 2.67 X | |||
| Revenue | 29.57 M | |||
| EBITDA | (449 K) | |||
| Net Income | 376 K | |||
| Cash Flow From Operations | (10.73 M) | |||
| Market Capitalization | 4.14 M | |||
| Total Asset | 42.9 M | |||
| Net Asset | 42.9 M |
About Clearside Biomedical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Clearside Biomedical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Clearside Biomedical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Clearside Biomedical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Clearside Stock Analysis
When running Clearside Biomedical's price analysis, check to measure Clearside Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Clearside Biomedical is operating at the current time. Most of Clearside Biomedical's value examination focuses on studying past and present price action to predict the probability of Clearside Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Clearside Biomedical's price. Additionally, you may evaluate how the addition of Clearside Biomedical to your portfolios can decrease your overall portfolio volatility.